{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_codes_comments in Code Comments (approximate match)
Status:
Possibly Marketed Outside US
First approved in 2012
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Re-Contour Eye by Van Laere LLC
(2018)
Source URL:
First approved in 2012
Source:
21 CFR 341
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125347
(2009)
Source URL:
First approved in 2009
Source:
BLA125347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2006
Source:
M032
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
First approved in 2001
Source:
Preferred Plus Urinary Pain Relief by Kinray
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02919657: Phase 4 Interventional Completed Analysis, Event History
(2016)
Source URL:
First approved in 1997
Source:
NaturVet ArthriSoothe by The Garmon Corporation
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Chlorhexidine FLUSH by Stratford Care Usa, Inc.
(2011)
Source URL:
First approved in 1991
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M006
(2011)
Source URL:
First approved in 1991
Source:
NDA019885
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NDA018029
(1955)
Source URL:
First approved in 1955
Source:
NDA018029
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2013)
Source URL:
First approved in 1954
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE